Top Story

SLNB used in patients with thin melanomas prior to guidelines

April 18, 2015

NEW YORK — Sentinel lymph node biopsy was used in patients with thin melanomas who did not have high-risk features and who had a very low risk for sentinel lymph node positivity prior to guidelines recommending against its use in this setting, according to observational study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.

Little evidence exists to support the routine use of sentinel lymph node biopsy (SLNB) in patients with T1 melanomas — or thin melanomas with Breslow’s depth less than 1 mm— according to guidelines published by ASCO and the Society of Surgical Oncology (SSO) in 2013. However, SLNB may be utilized in high-risk cases of thin melanomas, such as in patients who present with ulceration and/or a mitotic rate of at least 1/mm2, according to study background.

Meeting News Coverage

HD IL-2 extends OS in malignant melanoma

April 18, 2015
NEW YORK — Patients with metastatic melanoma treated with high-dose interleukin-2 demonstrated improved OS compared with historical reference standards, according…

Oncology Nursing Society to kick off its 40th Annual Congress

April 17, 2015
The Oncology Nursing Society will kick off its 2015 Annual Congress on Wednesday, April 22 in Orlando, Fla., marking its 40th year of providing comprehensive nursing…
FDA News

FDA grants orphan drug designation to Samcyprone for malignant stage IIb to IV melanoma

April 17, 2015
RXi Pharmaceuticals announced it has received orphan drug designation from the FDA for Samcyprone, its clinical candidate for treating malignant melanoma stage IIb to…
FDA News

FDA grants orphan drug designation to Reolysin for malignant gliomas

April 17, 2015
The FDA today granted orphan drug designation to pelareorep for the treatment of patients with malignant gliomas, according to a press release from the drug’s…
More News Headlines »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

VIDEO: Ongoing phase 3 trial evaluates patient-specific vaccine in metastatic melanoma

April 12, 2015
Robert O. Dillman, MD, vice president of oncology at NeoStem Inc., provides an overview of a phase 3 trial evaluating…
More »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »